phase II clinical study
Tempus, Actuate Therapeutics Ink Collaboration to Discover Biomarkers of Response for Elraglusib
Tempus will provide its clinical xF+ liquid biopsy and research-use-only DNA methylation tests to the ongoing Phase I/II trial of Actuate's GSK-3β inhibitor elraglusib.
Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.
Caris, Sorrento, Prostate Cancer Clinical Trial Consortium Ink Clinical Trial Partnership
The partners will use Caris' MI Profile to analyze samples from metastatic castration-resistant prostate cancer patients in Sorrento's Phase II Maverick trial.
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.